Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ralph Mazitschek

Showing results (121-130 of 136) with videos related to

Pageof 14
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|November 2, 2016
Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myelomaTeru Hideshima, Jun Qi, Ronald M Paranal, et al.
Nature Chemical Biology|May 28, 2026
Pharmacological targeting of IRF4 as a therapeutic strategy for multiple myelomaMichael P Agius, Chen Song, Qi Liu, et al.
Biorxiv : the Preprint Server for Biology|May 27, 2024
KBTBD4 Cancer Hotspot Mutations Drive Neomorphic Degradation of HDAC1/2 Corepressor ComplexesXiaowen Xie, Olivia Zhang, Megan J R Yeo, et al.
Chemistry & Biology|December 27, 2011
Identification and validation of tetracyclic benzothiazepines as Plasmodium falciparum cytochrome bc1 inhibitorsCarolyn K Dong, Sameer Urgaonkar, Joseph F Cortese, et al.
Nature|February 12, 2025
Converging mechanism of UM171 and KBTBD4 neomorphic cancer mutationsXiaowen Xie, Olivia Zhang, Megan J R Yeo, et al.
Cell Reports Methods|April 14, 2023
Diagnostic TR-FRET assays for detection of antibodies in patient samplesHong Yue, Radosław P Nowak, Daan Overwijn, et al.
Science Translational Medicine|May 22, 2015
The cytoplasmic prolyl-tRNA synthetase of the malaria parasite is a dual-stage target of febrifugine and its analogsJonathan D Herman, Lauren R Pepper, Joseph F Cortese, et al.
Biorxiv : the Preprint Server for Biology|May 27, 2024
Asymmetric Engagement of Dimeric CRL3 <sup>KBTBD4</sup> by the Molecular Glue UM171 Licenses Degradation of HDAC1/2 ComplexesMegan Jr Yeo, Olivia Zhang, Xiaowen Xie, et al.
Blood Cancer Journal|February 6, 2023
Correction: Prolyl-tRNA synthetase as a novel therapeutic target in multiple myelomaKeiji Kurata, Anna James-Bott, Mark A Tye, et al.
Blood Cancer Journal|January 11, 2023
Prolyl-tRNA synthetase as a novel therapeutic target in multiple myelomaKeiji Kurata, Anna James-Bott, Mark A Tye, et al.
Pageof 14

Showing results (121-130 of 136) with videos related to

Sort By:
Pageof 14
Proceedings of the National Academy of Sciences of the United States of America|November 2, 2016
Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myelomaTeru Hideshima, Jun Qi, Ronald M Paranal, et al.
Nature Chemical Biology|May 28, 2026
Pharmacological targeting of IRF4 as a therapeutic strategy for multiple myelomaMichael P Agius, Chen Song, Qi Liu, et al.
Biorxiv : the Preprint Server for Biology|May 27, 2024
KBTBD4 Cancer Hotspot Mutations Drive Neomorphic Degradation of HDAC1/2 Corepressor ComplexesXiaowen Xie, Olivia Zhang, Megan J R Yeo, et al.
Chemistry & Biology|December 27, 2011
Identification and validation of tetracyclic benzothiazepines as Plasmodium falciparum cytochrome bc1 inhibitorsCarolyn K Dong, Sameer Urgaonkar, Joseph F Cortese, et al.
Nature|February 12, 2025
Converging mechanism of UM171 and KBTBD4 neomorphic cancer mutationsXiaowen Xie, Olivia Zhang, Megan J R Yeo, et al.
Cell Reports Methods|April 14, 2023
Diagnostic TR-FRET assays for detection of antibodies in patient samplesHong Yue, Radosław P Nowak, Daan Overwijn, et al.
Science Translational Medicine|May 22, 2015
The cytoplasmic prolyl-tRNA synthetase of the malaria parasite is a dual-stage target of febrifugine and its analogsJonathan D Herman, Lauren R Pepper, Joseph F Cortese, et al.
Biorxiv : the Preprint Server for Biology|May 27, 2024
Asymmetric Engagement of Dimeric CRL3 <sup>KBTBD4</sup> by the Molecular Glue UM171 Licenses Degradation of HDAC1/2 ComplexesMegan Jr Yeo, Olivia Zhang, Xiaowen Xie, et al.
Blood Cancer Journal|February 6, 2023
Correction: Prolyl-tRNA synthetase as a novel therapeutic target in multiple myelomaKeiji Kurata, Anna James-Bott, Mark A Tye, et al.
Blood Cancer Journal|January 11, 2023
Prolyl-tRNA synthetase as a novel therapeutic target in multiple myelomaKeiji Kurata, Anna James-Bott, Mark A Tye, et al.
Pageof 14